OptiNose, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
68404V209
SEDOL
BMCF459
CIK
0001494650
www.optinose.com
LEI: 549300CPBME7Z3CYMN16
©
New: Infographics X-Lab
FIGI: BBG00HS39G73
OPTN
OptiNose, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Drug Manufacturers—Specialty & Generic
AI
PROFILER
NAME
OptiNose, Inc.
ISIN
US68404V2097
TICKER
OPTN
MIC
XNAS
REUTERS
OPTN.OQ
BLOOMBERG
OPTN US
F&G: 33
5.593,83 S&P · 23,73 Vola-Index · 94.510,51 BTC · 1,13285 EURUSD
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 29.04.2025       OptiNose
US68404V2097

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per sh...
weiterlesen
OptiNose
Research & Analysen Termsheet Terminal
Permalink
Fr., 21.03.2025       OptiNose
US68404V2097

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per sh...
weiterlesen
OptiNose
Research & Analysen Termsheet Terminal
Permalink
Do., 20.03.2025       OptiNose
US68404V2097

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of the proposed transaction, Paratek will acquire Optinose for $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the e...
weiterlesen
OptiNose
Research & Analysen Termsheet Terminal
Permalink
Do., 20.03.2025       OptiNose
US68404V2097

The Ademi Firm is investigating Optinose (NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In ...
weiterlesen
OptiNose
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S